GeoVax is a Biotechnology company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus - AIDS) and other infectious agents.
Our goals include: developing AIDS vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting phase I/II and III human trials for vaccine safety and effectiveness and obtaining regulatory approval of these vaccines in the USA and specified international markets.
Outstanding preclinical results: GeoVax DNA/MVA vaccine protected 96% of non-human primates for over 3˝ yrs. To our knowledge, this level of protection has not been achieved by other candidate vaccines.
Successful Phase I Human clinical DNA vaccine trials have demonstrated the safety of our vaccine(details).
After receiving ”Safe to Proceed” status for a new Investigational New Drug (IND) by the U.S. Food and Drug Administration (FDA), Phase IA/IB trial (1/10th dose) combining DNA with MVA began in May 2006. Another trial (full dose) began in September 2006. These trials test various combinations and doses of our DNA and MVA AIDS vaccines in human volunteers for their ability to raise Anti-AIDS immune responses as well as for their safety.
Long term, we expect that GeoVax will enter into agreements to out-license manufacturing technology to major vaccine production companies and distribution rights to key companies in several global markets in return for upfront fees, collaborative development agreements, and royalties on sales and distribution revenues. Internal vaccine manufacture and sale will be considered by GeoVax.